J Cancer 2012; 3:257-261. doi:10.7150/jca.3491 This volume
Cetuximab in Refractory Skin Cancer Treatment
1. Department of Internal Medicine
2. Division of Hematology/Oncology, Department of Internal Medicine
3. Department of Medical Microbiology
4. Division of Otolaryngology Head and Neck Surgery, Department of Surgery,
5. Division of Dermatology, Department of Internal Medicine, Southern Illinois University School of Medicine;
6. Simmons Cancer Institute at SIU, Springfield, IL.
Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in Refractory Skin Cancer Treatment. J Cancer 2012; 3:257-261. doi:10.7150/jca.3491. Available from https://www.jcancer.org/v03p0257.htm
Objectives: Non-melanoma skin cancer is the most common malignancy in US, with an annual incidence of in excess of 1.5 million cases. In the majority of cases, locoregional treatment is curative and systemic therapy is not indicated. Platinum-based chemotherapy regimens have been used most commonly in refractory cases. The use of cetuximab, a monoclonal antibody targeting epidermal growth factor receptor [EGFR], has been reported for skin cancer treatment. This current study evaluated eight cases of locally advanced and refractory basal cell or squamous cell cancers which were treated with cetuximab.
Methods: This is a retrospective study on eight patients who had received cetuximab for treatment of cutaneous carcinoma since 2007 at Southern Illinois University School of Medicine (SIU-SOM) Medical Oncology clinic.
Results: Three of the four patients with basal cell carcinoma and two of the four patients with squamous cell carcinoma maintained remission on treatment.. The main side effect was acneiform rash which required termination of treatment for one patient and dose reduction in another.
Conclusion: The study indicates that cetuximab may have a beneficial role for patients with non-melanoma cutaneous carcinomas that are refractory to standard therapy.
Keywords: cetuximab, non-melanoma, skin cancer